Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noah M Hahn

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Urology Case Reports|May 9, 2017
Port Site Recurrence Following a Robotic Laparoscopic Radical Nephroureterectomy for Sarcomatoid Variant of Urothelial CarcinomaJonathan Elliott Katz, Trinity J Bivalacqua, Noah M Hahn, et al.
Plos Genetics|August 9, 2018
Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancerDeepika Dhawan, Noah M Hahn, José A Ramos-Vara, et al.
Urologic Oncology|November 10, 2021
Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancerRosa Nadal, Andrea B Apolo, Daniel M Girardi, et al.
Clinical Genitourinary Cancer|October 16, 2013
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related eventNoah M Hahn, Constantin T Yiannoutsos, Kristina Kirkpatrick, et al.
International Journal of Genomics|May 11, 2017
Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer DrugsChristopher M Fulkerson, Deepika Dhawan, Timothy L Ratliff, et al.
Expert Opinion on Therapeutic Targets|April 19, 2012
Novel molecular targets for the therapy of urothelial carcinomaBagi R P Jana, Matthew D Galsky, Noah M Hahn, et al.
Clinical Genitourinary Cancer|April 30, 2024
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab VedotinEvangelia Vlachou, Ronac Mamtani, Noah M Hahn, et al.
Future Oncology (London, England)|March 23, 2011
Hypomethylating agents for urologic cancersAjjai S Alva, Noah M Hahn, Ana M Aparicio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malateNoah M Hahn, Maria Reckova, Liang Cheng, et al.
World Journal of Urology|October 22, 2015
Immune checkpoint inhibitors: a new frontier in bladder cancerMax Kates, Nikolai A Sopko, Hotaka Matsui, et al.
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Urology Case Reports|May 9, 2017
Port Site Recurrence Following a Robotic Laparoscopic Radical Nephroureterectomy for Sarcomatoid Variant of Urothelial CarcinomaJonathan Elliott Katz, Trinity J Bivalacqua, Noah M Hahn, et al.
Plos Genetics|August 9, 2018
Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancerDeepika Dhawan, Noah M Hahn, José A Ramos-Vara, et al.
Urologic Oncology|November 10, 2021
Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancerRosa Nadal, Andrea B Apolo, Daniel M Girardi, et al.
Clinical Genitourinary Cancer|October 16, 2013
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related eventNoah M Hahn, Constantin T Yiannoutsos, Kristina Kirkpatrick, et al.
International Journal of Genomics|May 11, 2017
Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer DrugsChristopher M Fulkerson, Deepika Dhawan, Timothy L Ratliff, et al.
Expert Opinion on Therapeutic Targets|April 19, 2012
Novel molecular targets for the therapy of urothelial carcinomaBagi R P Jana, Matthew D Galsky, Noah M Hahn, et al.
Clinical Genitourinary Cancer|April 30, 2024
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab VedotinEvangelia Vlachou, Ronac Mamtani, Noah M Hahn, et al.
Future Oncology (London, England)|March 23, 2011
Hypomethylating agents for urologic cancersAjjai S Alva, Noah M Hahn, Ana M Aparicio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malateNoah M Hahn, Maria Reckova, Liang Cheng, et al.
World Journal of Urology|October 22, 2015
Immune checkpoint inhibitors: a new frontier in bladder cancerMax Kates, Nikolai A Sopko, Hotaka Matsui, et al.
Pageof 14